Similarly, poor RFS was also seen among patients with higher FOXP3 expression in HER2−/ER+ breast cancer (P<0.0001, n = 832, Kaplan-Meier Estimates survival analysis, Figure 6), and the median RFS in tumors with high expression and others were 7.83 and 15.93 years, respectively. This evidence concerns the gene FOXP3 and breast carcinoma.